Wordt geladen...
Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
BACKGROUND AND OBJECTIVE: Emicizumab is a monoclonal antibody that bridges activated coagulation factor IX and factor X to restore effective hemostasis in persons with hemophilia A. It is indicated for routine prophylaxis of bleeding episodes in persons with hemophilia A. The aim of the present stud...
Bewaard in:
| Gepubliceerd in: | Clin Pharmacokinet |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer International Publishing
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8249270/ https://ncbi.nlm.nih.gov/pubmed/33709296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-021-01006-0 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|